[Barcelona, April 17th 2024] Barcelona Liver Bioservices (BLB) is pleased to announce a non-exclusive partnership with the global healthcare company Novo Nordisk aimed at characterizing the effects of novel chemical entities developed by Novo Nordisk for the treatment of chronic liver disease.

Chronic liver disease, along with its primary non-neoplastic complication, portal hypertension, stands as a significant global health challenge, marked by its high prevalence, leading cause of mortality, and economic burden. Despite these pressing concerns, safe and effective treatments remain elusive.

Under the terms of the agreement, BLB will leverage its diverse proprietary models of liver disease to explore the efficacy and underlying molecular mechanisms of Novo Nordisk’s best-in-class compounds, positioning them as potential treatments for chronic liver disease and portal hypertension.

Jordi Gracia-Sancho, Chief Scientific Officer at BLB, expressed enthusiasm about the collaboration: “Novo Nordisk has recognized the quality and usefulness of our pre-clinical solutions to accelerate the development of new therapeutics for liver diseases. We are keen on this new collaboration and the potential it holds to make a meaningful impact on liver disease management”.

This partnership represents a significant step forward in the quest to address the unmet medical needs of individuals suffering from chronic liver disease and portal hypertension. By combining expertise and resources, BLB and Novo Nordisk aim to bring innovative treatments closer to reality, offering hope to millions worldwide.

BLB provides valuable insights into complex disease pathways and drug responses in a more meaningful liver disease context. BLB specializes in in vivo, ex vivo and in vitro models of liver disease, including hepatic hemodynamics, histology, imaging, molecular biology, advanced cell culture systems and bioinformatics. For more information about the services and research developed by BLB please visit

[Boston, Nov 11th 2023] — Barcelona Liver Bioservices, a leading research and development company specializing in liver disease studies, in collaboration with Gilead Sciences, a global biopharmaceutical company dedicated to advancing innovative therapies, is excited to announce the results of an original study that showcases the potential of targeting the LPA pathway in the treatment of advanced chronic liver disease. The results of this research study will be presented today as poster 2456-C, during the annual meeting of the American Association for the Study of Liver Diseases.

Chronic liver disease affects millions of people worldwide, leading to severe health complications and limited therapeutic options. With this in mind, Barcelona Liver Bioservices and Gilead Sciences embarked on a collaborative research endeavor to investigate the Lysophosphatidic Acid (LPA) pathway’s role in advanced chronic liver disease and its potential as a therapeutic target.

The study, which involved preclinical models mimicking advanced chronic liver disease, revealed remarkable findings, including:

1. Significant improvement in portal hypertension and fibrosis: Targeting the LPA pathway led to a substantial improvement in liver microcirculatory function, with a reduction in portal pressure and liver fibrosis and inflammation.

2. Reduced inflammation and oxidative stress: The therapy targeting the LPA pathway also demonstrated a notable reduction in inflammatory and oxidative markers.

3. Improved sinusoidal cells phenotype: Inhibition of the LPA pathway promoted amelioration in the phenotype and function of liver sinusoidal endothelial cells and hepatic stellate cells.

Commenting on the study’s results, Prof Jordi Gracia-Sancho, CSO of Barcelona Liver Bioservices, said, “We are thrilled to reveal the potential of targeting the LPA pathway in models of advanced chronic liver disease. This discovery has the power to transform the landscape of liver disease treatment and provide hope to millions of individuals suffering from this condition.”

About Barcelona Liver Bioservices:

Barcelona Liver Bioservices is a leading research and development company specializing in liver disease studies. The organization is dedicated to advancing our understanding of liver diseases and developing innovative research models to ultimately improve the lives of patients worldwide. For more info: 

Disclaimer: This press release contains forward-looking statements, and actual results may differ materially. Please refer to the companies’ official documents and statements for the most accurate information.

Barcelona Liver Bioservices is excited to announce its active participation in the 2nd edition of the International Workshop on Liver and Gut Fibrosis, held in Valencia on 26 & 27 October 2023. This year, we are honored to present two unique posters that exemplify our commitment to advancing the understanding and treatment of liver fibrosis.

Study 1: Unveiling the impact of GTX-011 in human precision cut liver slices.

Our first poster shines a spotlight on our groundbreaking research investigating the effects of GTX-011 in liver tissues. GTX-011, a novel therapeutic agent developed by our partner GAT Therapeutics, has demonstrated promising potential in the treatment of liver fibrosis. Our research delves into the molecular and cellular changes induced by GTX-011, offering insights into its mechanism of action.

Our findings not only elucidate the efficacy of GTX-011 but also provide a critical step toward the development of more effective treatments for liver fibrosis. The study combines the use of PCLS together with advanced bioinformatic analysis.

Study 2: Exploring the impact of gender in chronic liver disease pathophysiology

Our second poster investigates a vital yet often overlooked aspect of chronic liver disease pathophysiology – the role of sex. Sex-related differences in the progression and outcome of liver diseases have long been recognized, and our research sheds light on these differences. We examine how sex influences disease development, progression, and therapeutic responses.

Understanding the impact of sex in liver disease pathophysiology is a key step toward more personalized and effective medical interventions. The insights gleaned from this research may ultimately lead to tailored treatment strategies that consider sex-based differences, enhancing the care and outcomes of patients with chronic liver diseases.

Barcelona Liver Bioservices is honored to present two significant studies at the International Workshop on Gut and Liver Fibrosis. Our tireless dedication to advancing liver fibrosis research and improving patient care is evident in the diverse and groundbreaking studies we showcase. We eagerly anticipate engaging with experts, exchanging insights, and forging collaborations that will drive progress in our ongoing battle against liver fibrosis. Watch this space for further updates as we continue to make impactful strides in the field of liver research.

Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today the presentation of an original communication at The EASL Congress held in Vienna and organized by the European Association for the Study of Liver Diseases (EASL).

Poster #WED-524 “GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices” will be presented from 13:00 – 14:30h by Prof Dr Jordi Gracia-Sancho, co-founder and CSO of BLB. The study assesses the effects of GTX-011, a first-in-class drug with anti-inflammatory and anti-fibrotic properties mediated by the inhibition of the TGFβ pathway, in Precision-Cut Liver Slices (PCLS) from human liver tissues. PCLS represent a unique 3D ex vivo model that preserves the structure and cellular composition of the liver, constituting an intermediate step between pre-clinical and clinical research.

The results of this study revealed that treatment of human liver slices with GTX-011 promoted hepatic stellate cells (HSCs) de-activation and inhibition of pro-fibrogenic pathways. Furthermore, gene deconvolution analysis was performed combining our transcriptomic data with previously published single-cell RNAseq data, in order to better understand the changes in the phenotype of each liver cell type in response to treatment. This advanced bioinformatic analysis confirmed the effects of GTX-011 on HSCs, promoting their de-activation compared to vehicle-treated tissues. 

For more information about the company and available research services, including liver-on-a-chip technology, human PCLS, preclinical models of liver diseases, and refined bioinformatic analysis, among others, please visit

Barcelona Liver Bioservices (BLB) announced today the presentation of an original communication at the annual meeting of the American Association for the Study of the Liver (AASLD), held as The Liver Meeting Digitial Experience.

Poster #1914 “GTX-011 improves portal hypertension, liver fibrosis and endothelial dysfunction in a rat model of non-alcoholic steatohepatitis” will be presented by Zoe Boyer, Senior Associate Scientist at BLB. The study, fruit of the collaboration between BLB and GAT Therapeutics, describes for the first time the effects of the novel non-steroidal modulator of 3C nuclear receptors GTX-011 in a pre-clinical model of NASH. Results of the study show that rats receiving GTX-011 exhibited significant improvement in portal hypertension, considered the most detrimental complication of advanced liver disease. Underlying mechanisms of this hemodynamic improvement included amelioration of liver sinusoidal endothelial cells (showing improved vasodilator and anti-inflammatory mediators), together with amelioration in the metabolic profile (reduced FFA and insulin resistance). Importantly, GTX-011 administration led to partial de-activation of hepatic stellate cells. “We are glad to describe in detail the benefits of this compound in a pre-clinical model of NASH that particularly recapitulates the main pathophysiological features and transcriptome de-regulations of the human disease”, stated Dr Gracia-Sancho, co-founder and CSO of BLB.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. For more information about the company, our publications and available research services please visit